Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials

详细信息    查看全文

• 作者：Yoonsun Mo ; MS ; Pharm.D. ; BCPS ; BCCCP^a ; ^b ; ^{yoonsun.mo@wne.edu" class="auth_mail" title="E-mail the corresponding author} ; Michael C. Thomas ; Pharm.D. ; BCPS ; FCCP^a ; ¹ ; ^{michael.thomas@wne.edu" class="auth_mail" title="E-mail the corresponding author} ; George E. Karras Jr. ; MD ; FCCM^b ; ² ; ^{George.Karras@sphs.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Barbiturates ; Phenobarbital ; Benzodiazepines ; Alcohol withdrawal syndrome ; Delirium tremens ; Systematic review
• 刊名：Journal of Critical Care
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：32
• 期：Complete
• 页码：101-107
• 全文大小：306 K

文摘

To perform a systematic review of the clinical trials concerning the use of barbiturates for the treatment of acute alcohol withdrawal syndrome (AWS).

Materials and Methods

A literature search of MEDLINE, EMBASE, and the Cochrane Library, together with a manual citation review was conducted. We selected English-language clinical trials (controlled and observational studies) evaluating the efficacy and safety of barbiturates compared with benzodiazepine (BZD) therapy for the treatment of AWS in the acute care setting. Data extracted from the included trials were duration of delirium, number of seizures, length of intensive care unit and hospital stay, cumulated doses of barbiturates and BZDs, and respiratory or cardiac complications.

Results

Seven studies consisting of 4 prospective controlled and 3 retrospective trials were identified. Results from all the included studies suggest that barbiturates alone or in combination with BZDs are at least as effective as BZDs in the treatment of AWS. Furthermore, barbiturates appear to have acceptable tolerability and safety profiles, which were similar to those of BZDs in patients with AWS.

Conclusions

Although the evidence is limited, based on our findings, adding phenobarbital to a BZD-based regimen is a reasonable option, particularly in patients with BZD-refractory AWS.